Journals / Eurasian Journal of Pulmonology / 2021 / Cilt: 23 - Sayı: 3

The usefulness of Palliative Prognostic Index in predicting the survival of patients with advanced lung cancer

Pages
174–179
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The overall mean age was 64.59 ± 10.87 years; 97% of the patients died during the follow-up period.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:BACKGROUND AND AIM: In advanced cancer patients, life expectancy is essential in making end-of-life decisions for clinicians and patients.
📊
Key Findings & Data:The patients were divided into three groups according to their PPI score: group A: PPI ≤4, Group B: 4 6.
💡
Conclusion & Impact:The overall mean age was 64.59 ± 10.87 years; 97% of the patients died during the follow-up period.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

BACKGROUND AND AIM: In advanced cancer patients, life expectancy is essential in making end-of-life decisions for clinicians and patients. Palliative Prognostic Index (PPI) is a prognostic tool commonly used in palliative care for prediction survival. The aim of this study is to evaluate the accuracy of PPI for predicting survival in patients with advanced lung cancer. MATERIALS AND METHODS: Patients with advanced lung cancer hospitalized in a palliative clinic were included in this retrospective study. The PPI score was calculated by the doctor on admission day. The patients were divided into three groups according to their PPI score: group A: PPI ≤4, Group B: 4 6. All patients were followed up for up to 3 months. The survival analyses were performed using the Kaplan–Meier analysis. RESULTS: There were 177 (87.2%) men for a total of 203 patients with advanced lung cancer included in the study. The overall mean age was 64.59 ± 10.87 years; 97% of the patients died during the follow-up period. Their overall median survival was 17 days. The median survival for Group A (51 days, 95% confidence interval [CI]: 39.7–62.2) was significantly longer than Group B (16 days, 95% CI: 10.4–21.5) and Group C (6 days, 95% CI: 4–7.9). For a PPI ≤4 and 6‑week survival, the sensitivity and specificity were 82.5% and 75.7%, respectively. For a PPI >6 and 3‑week survival, the sensitivity and specificity were 57.7% and 91.3%, respectively. CONCLUSION: The PPI is a valuable and useful prognostic tool in predicting survival time for advanced lung cancer patients in palliative care.

🔖

Cite This Article

ARAS, G., AKIN, F. S. (2022). The usefulness of Palliative Prognostic Index in predicting the survival of patients with advanced lung cancer. Eurasian Journal of Pulmonology, Cilt: 23 - Sayı: 3, 174–179. https://ajindex.com/articles/509575

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Salpeter SR, Malter DS, Luo EJ, Lin AY, Stuart B. Systematic review of cancer presentations with a median survival of six months or less. J Palliat Med 2012;15:175‑85
  2. Anshushaug M, Gynnild MA, Kaasa S, Kvikstad A, Grønberg BH. Characterization of patients receiving palliative chemo‑ and radiotherapy during end of life at a regional cancer center in Norway. Acta Oncol 2015;54:395‑402
  3. Haque W, Verma V, Butler EB, Teh BS. Patterns of end‑of‑life oncologic care for Stage IV non‑small cell lung cancer in the United States. Anticancer Res 2019;39:3137‑40
  4. Colombet I, Bouleuc C, Piolot A, Vilfaillot A, Jaulmes H, Voisin‑Saltiel S, et al. Multicentre analysis of intensity of care at the end‑of‑life in patients with advanced cancer, combining health administrative data with hospital records: Variations in practice call for routine quality evaluation. BMC Palliat Care 2019;18:35
  5. Christakis NA, Lamont EB. Extent and determinants of error in doctors’ prognoses in terminally ill patients: Prospective cohort study. BMJ 2000;320:469‑72
  6. Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, et al. Prognostic factors in advanced cancer patients: Evidence‑based clinical recommendations – A study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 2005;23:6240‑8
  7. Morita T, Tsunoda J, Inoue S, Chihara S. The Palliative Prognostic Index: A scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer 1999;7:128‑33
  8. Anderson F, Downing GM, Hill J, Casorso L, Lerch N. Palliative performance scale (PPS): A new tool. J Palliat Care 1996;12:5‑11
  9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington: American Psychiatric Publishing, Inc.; 1989
  10. Stone CA, Tiernan E, Dooley BA. Prospective validation of the palliative prognostic index in patients with cancer. J Pain Symptom Manage 2008;35:617‑22
  11. Yoong J, Atkin N, Le B. Use of the palliative prognostic index in a palliative care consultation service in Melbourne, Australia. J Pain Symptom Manage 2010;39:e2‑4
  12. Maltoni M, Scarpi E, Pittureri C, Martini F, Montanari L, Amaducci E, et al. Prospective comparison of prognostic scores in palliative care cancer populations. Oncologist 2012;17:446‑54
  13. Alshemmari S, Ezzat H, Samir Z, Refaat S, Alsirafy SA. The palliative prognostic index for the prediction of survival and in‑hospital mortality of patients